• RAPT Therapeutics Inc (NASDAQ: RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share.

• The price represents a 6% discount from last the close price of $35.19 on Tuesday.

• Gross proceeds of approximately $125 million will be used to fund the R&D of FLX475, RPT193, and other potential future drug candidates, general & administrative expenses, and capital expenditures.

• Underwriters have an option to purchase up to an additional 568k shares.

• The offering will close by June 18.

• Recently, the company announced positive data from Phase 1b trial of RPT193 in atopic dermatitis, demonstrating a 36.3% improvement from baseline in the Eczema disease severity score, compared to 17.0% in the placebo group.

• RAPT plans to initiate a dose-ranging Phase 2b study in moderate-to-severe atopic dermatitis and a Phase 2a study in asthma with RPT193.

• See the Offer Prospectus here.

• Price Action: RAPT shares are down 2.67% at $34.25 during the premarket session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.